» Articles » PMID: 23591266

The Need for Multicentre Cardiovascular Clinical Trials in Asia

Overview
Journal Nat Rev Cardiol
Date 2013 Apr 18
PMID 23591266
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Historically, the USA and European countries have been the dominant figures in medical research. However, in the past 10 years, Asia has emerged as a new 'hot spot' for clinical research owing to the tremendous potential generated by steady economic growth, remarkable advances in research and development capacity, and an expanding population. However, investigators involved with the set-up and conduct of multicentre trials in such a vast and heterogeneous continent face huge challenges-bridging the fundamental differences between the Asian countries, such as languages, resources, regulatory procedural timelines, and the general understanding of clinical research. In this Perspectives article, we explain why Asia should be established as a hub for large multicentre trials, discuss the challenges involved, and highlight the importance of a strong collaborative infrastructure for multiple investigational sites in this culturally diverse continent.

Citing Articles

Federated learning for multi-center imaging diagnostics: a simulation study in cardiovascular disease.

Linardos A, Kushibar K, Walsh S, Gkontra P, Lekadir K Sci Rep. 2022; 12(1):3551.

PMID: 35241683 PMC: 8894335. DOI: 10.1038/s41598-022-07186-4.


Independent Predictors of Cardiac Mortality and Hospitalization for Heart Failure in a Multi-Ethnic Asian ST-segment Elevation Myocardial Infarction Population Treated by Primary Percutaneous Coronary Intervention.

Bulluck H, Zheng H, Chan M, Foin N, Foo D, Lee C Sci Rep. 2019; 9(1):10072.

PMID: 31296912 PMC: 6624280. DOI: 10.1038/s41598-019-46486-0.


Development of local clinical practice guidelines in the real world: an evolving scene in China.

Kwong J, Sun X Heart Asia. 2018; 9(2):e010903.

PMID: 29467835 PMC: 5818048. DOI: 10.1136/heartasia-2017-010903.


Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia.

Edwards F, Arkell P, Fong , Roberts L, Gendy D, Wong C J Thromb Thrombolysis. 2013; 38(2):226-34.

PMID: 24233388 DOI: 10.1007/s11239-013-1017-6.

References
1.
Thompson D, Oldridge N, Yu D, Yu C . Translation and validation of two Chinese health-related quality of life instruments in patients with coronary heart disease. Hong Kong Med J. 2009; 15 Suppl 2:8-11. View

2.
Ogawa S, Shinohara Y, Kanmuri K . Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-. Circ J. 2011; 75(8):1852-9. DOI: 10.1253/circj.cj-10-1183. View

3.
Yu D, Thompson D, Yu C, Oldridge N . Assessing HRQL among Chinese patients with coronary heart disease: angina, myocardial infarction and heart failure. Int J Cardiol. 2008; 131(3):384-94. DOI: 10.1016/j.ijcard.2007.10.043. View

4.
Moher D, Jones A, Lepage L . Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001; 285(15):1992-5. DOI: 10.1001/jama.285.15.1992. View

5.
. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J. 2010; 74(11):2479-500. DOI: 10.1253/circj.cj-88-0001. View